Tags

Type your tag names separated by a space and hit enter

Efficacy of a trivalent Haemophilus paragallinarum vaccine compared to bivalent vaccines.

Abstract

The efficacy of a trivalent oil-adjuvant Coryza vaccine containing serotypes A, B and C of Haemophilus paragallinarum has been compared with that of a bivalent oil-adjuvant Coryza vaccine containing serotypes A and C and that of a commercially available, bivalent A1(OH)3-potentiated vaccine, containing types A and C. The trivalent vaccine, given at 10 and 17 weeks of age, provided the best protection. Even at 55 weeks after booster vaccination, chickens were still significantly protected, following severe challenge with either of the three serotypes of Haemophilus paragallinarum. Both bivalent vaccines did not protect against type B challenge. Furthermore the oil-adjuvant vaccines induced higher HI-A titers, which correlate with protection, compared to the A1(OH)3-potentiated vaccine. The results show that type B strains are pathogenic and constitute a distinct immunotype and thus a Coryza vaccine should contain three serotypes to obtain a broader protection against all serotypes.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Bacteriological Research Department, Intervet International B.V., Boxmeer, Netherlands.

    ,

    Source

    Veterinary microbiology 32:1 1992 Jul pg 43-9

    MeSH

    Adjuvants, Immunologic
    Animals
    Antibodies, Bacterial
    Bacterial Vaccines
    Chick Embryo
    Chickens
    Haemophilus
    Haemophilus Infections
    Hemagglutination Inhibition Tests
    Immunization, Secondary
    Poultry Diseases
    Respiratory Tract Infections
    Vaccination

    Pub Type(s)

    Comparative Study
    Journal Article

    Language

    eng

    PubMed ID

    1514236

    Citation

    Jacobs, A A., et al. "Efficacy of a Trivalent Haemophilus Paragallinarum Vaccine Compared to Bivalent Vaccines." Veterinary Microbiology, vol. 32, no. 1, 1992, pp. 43-9.
    Jacobs AA, Cuenen W, Storm PK. Efficacy of a trivalent Haemophilus paragallinarum vaccine compared to bivalent vaccines. Vet Microbiol. 1992;32(1):43-9.
    Jacobs, A. A., Cuenen, W., & Storm, P. K. (1992). Efficacy of a trivalent Haemophilus paragallinarum vaccine compared to bivalent vaccines. Veterinary Microbiology, 32(1), pp. 43-9.
    Jacobs AA, Cuenen W, Storm PK. Efficacy of a Trivalent Haemophilus Paragallinarum Vaccine Compared to Bivalent Vaccines. Vet Microbiol. 1992;32(1):43-9. PubMed PMID: 1514236.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Efficacy of a trivalent Haemophilus paragallinarum vaccine compared to bivalent vaccines. AU - Jacobs,A A, AU - Cuenen,W, AU - Storm,P K, PY - 1992/7/1/pubmed PY - 1992/7/1/medline PY - 1992/7/1/entrez SP - 43 EP - 9 JF - Veterinary microbiology JO - Vet. Microbiol. VL - 32 IS - 1 N2 - The efficacy of a trivalent oil-adjuvant Coryza vaccine containing serotypes A, B and C of Haemophilus paragallinarum has been compared with that of a bivalent oil-adjuvant Coryza vaccine containing serotypes A and C and that of a commercially available, bivalent A1(OH)3-potentiated vaccine, containing types A and C. The trivalent vaccine, given at 10 and 17 weeks of age, provided the best protection. Even at 55 weeks after booster vaccination, chickens were still significantly protected, following severe challenge with either of the three serotypes of Haemophilus paragallinarum. Both bivalent vaccines did not protect against type B challenge. Furthermore the oil-adjuvant vaccines induced higher HI-A titers, which correlate with protection, compared to the A1(OH)3-potentiated vaccine. The results show that type B strains are pathogenic and constitute a distinct immunotype and thus a Coryza vaccine should contain three serotypes to obtain a broader protection against all serotypes. SN - 0378-1135 UR - https://www.unboundmedicine.com/medline/citation/1514236/Efficacy_of_a_trivalent_Haemophilus_paragallinarum_vaccine_compared_to_bivalent_vaccines_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0378-1135(92)90005-E DB - PRIME DP - Unbound Medicine ER -